Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
PUBLIC HEALTH: Enhanced: A Sound Rationale Needed for Phase III HIV-1 Vaccine Trials
Dennis R. Burton,1 Ronald C. Desrosiers,2 Robert W. Doms,3 Mark B. Feinberg,4 Robert C. Gallo,5 Beatrice Hahn,6 James A. Hoxie,3 Eric Hunter,6 Bette Korber,7 Alan Landay,8 Michael M. Lederman,9 Judy Lieberman,2 Joseph M. McCune,10 John P. Moore,11 Neal Nathanson,3 Louis Picker,12 Douglas Richman,13 Charles Rinaldo,14 Mario Stevenson,15 David I. Watkins,16 Steven M. Wolinsky,17 Jerome A. Zack18
Concerns are expressed by a group of AIDS researchers about the U.S. government's plans to conduct a phase III trial of a combination HIV-1 vaccine in Thailand despite the cancellation of a trial of a very similar combination vaccine in the U.S.A. last year. One of the vaccine components, recombinant monomeric gp120, has already been shown to be ineffective in phase III trials in Thailand and the United States; the other component, a recombinant canarypox vector, is also poorly immunogenic. The scientific rationale that has been offered for the new trial in Thailand is considered by the authors to be weak.
1The Scripps Research Institute, La Jolla, CA; 2Harvard Medical School, Boston, MA; 3University of Pennsylvania, Philadelphia, PA; 4Emory University, Atlanta, GA; 5Institute of Human Virology, Baltimore, MD; 6University of Alabama at Birmingham; 7Santa Fe Institute, Santa Fe, NM; 8Rush Medical College, Chicago, IL; 9Case-Western Reserve University, Cleveland, OH; 10The Gladstone Institute for Virology and Immunology, San Francisco, CA; 11Weill Medical College of Cornell University, New York, NY; 12Oregon Health and Science University, Portland, OR; 13University of California, San Diego, and San Diego Veterans Affairs Healthcare System; 14University of Pittsburgh, Pittsburgh, PA; 15University of Massachusetts Medical School, Worcester, MA; 16University of Wisconsin, Madison, WI; 17Northwestern University, Chicago, IL; 18University of California, Los Angeles, CA, USA.
The editors suggest the following Related Resources on Science sites:
In Science Magazine
LETTERS
Robert Belshe, Genoveffa Franchini, Marc P. Girard, Frances Gotch, Pontiano Kaleebu, Marta L. Marthas, Michael B. McChesney, Rose McCullough, Fred Mhalu, Dominique Salmon-Ceron, Rafick-Pierre Sekaly, Koen Van Rompay, Bernard Verrier, Britta Wahren, Mercedes Weissenbacher;, The AIDS Vaccine Advocacy Coalition;, Dennis R. Burton, Ronald C. Desrosiers, Robert W. Doms, Mark B. Feinberg, Beatrice H. Hahn, James A. Hoxie, Eric Hunter, Bette T. M. Korber, Alan L. Landay, Michael M. Lederman, Judy Lieberman, Joseph M. McCune, John P. Moore, Neal Nathanson, Louis Picker, Douglas D. Richman, Charles R. Rinaldo, Mario Stevenson, David I. Watkins, Steven M. Wolinsky, Jerome A. Zack;, and Robert C. Gallo (9 July 2004) Science305 (5681), 177b.
[DOI: 10.1126/science.305.5681.177b] |Full Text »|PDF »
LETTERS
Richard Jefferys, Mark Harrington;, John G. McNeil, Margaret I. Johnston, Edmund C. Tramont, and Deborah L. Birx (9 July 2004) Science305 (5681), 180a.
[DOI: 10.1126/science.305.5681.180a] |Full Text »|PDF »
LETTERS
Charal Trinvuthipong (13 February 2004) Science303 (5660), 954c.
[DOI: 10.1126/science.303.5660.954c] |Full Text »|PDF »
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
HIV Vaccine Trial Results -- An Opening for Further Research.
T-Cell Vaccine Strategies for Human Immunodeficiency Virus, the Virus with a Thousand Faces.
B. T. Korber, N. L. Letvin, and B. F. Haynes (2009)
J. Virol.
83, 8300-8314
|Full Text »|PDF »
Systemic Immunization with an ALVAC-HIV-1/Protein Boost Vaccine Strategy Protects Rhesus Macaques from CD4+ T-Cell Loss and Reduces both Systemic and Mucosal Simian-Human Immunodeficiency Virus SHIVKU2 RNA Levels..
R. Pal, D. Venzon, S. Santra, V. S. Kalyanaraman, D. C. Montefiori, L. Hocker, L. Hudacik, N. Rose, J. Nacsa, Y. Edghill-Smith, et al. (2006)
J. Virol.
80, 3732-3742
|Abstract »|Full Text »|PDF »
Protection of Rhesus Monkeys against Infection with Minimally Pathogenic Simian-Human Immunodeficiency Virus: Correlations with Neutralizing Antibodies and Cytotoxic T Cells.
G. V. Quinnan Jr., X.-F. Yu, M. G. Lewis, P. F. Zhang, G. Sutter, P. Silvera, M. Dong, A. Choudhary, P. T. N. Sarkis, P. Bouma, et al. (2005)
J. Virol.
79, 3358-3369
|Abstract »|Full Text »|PDF »
CXCR4-Dependent Infection of CD8+, but Not CD4+, Lymphocytes by a Primary Human Immunodeficiency Virus Type 1 Isolate.
B. Zerhouni, J. A. E. Nelson, and K. Saha (2004)
J. Virol.
78, 12288-12296
|Abstract »|Full Text »|PDF »
Evolutionary Dynamics of the Glycan Shield of the Human Immunodeficiency Virus Envelope during Natural Infection and Implications for Exposure of the 2G12 Epitope.
L. Dacheux, A. Moreau, Y. Ataman-Onal, F. Biron, B. Verrier, and F. Barin (2004)
J. Virol.
78, 12625-12637
|Abstract »|Full Text »|PDF »
Development of an AIDS vaccine: perspective from the South African AIDS Vaccine Initiative.
T. J Tucker and G. Mazithulela (2004)
BMJ
329, 454-456
|Full Text »|PDF »
